Acrivon Therapeutics Gets FDA's Breakthrough Designation for Cancer Assay
November 28 2023 - 8:58AM
Dow Jones News
By Dean Seal
Acrivon Therapeutics said federal regulators have granted
breakthrough device designation for its ACR-368 OncoSignature
assay, which is being developed to identify ovarian cancer patients
who may benefit from ACR-368 treatment.
The Watertown, Mass.-based company said the U.S. Food and Drug
Administration's designation will help get patients and healthcare
providers more timely access to its medical device by speeding up
the development, assessment and review processes for premarket
approval and marketing authorization.
Chief Executive Peter Blume-Jensen said the assay is being
developed to predict tumor sensitivity to ACR-368 and used in
ongoing clinical studies.
Breakthrough device designation is granted to devices that may
provide more effective treatment or diagnosis of life-threatening
or irreversibly debilitating diseases or conditions for which no
approved alternative exists.
"We believe this designation is the first of its kind for such
an assay, and represents yet another powerful validation of our
[Acrivon Predictive Precision Proteomics] platform," Blume-Jensen
said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 08:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From Apr 2024 to May 2024
Acrivon Therapeutics (NASDAQ:ACRV)
Historical Stock Chart
From May 2023 to May 2024